Best Oncology Companies in Tokyo, Japan
The 36 best Oncology companies in Tokyo, Japan in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Anaeropharma.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Tokyo
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Anaeropharma Hypoxic environment targeted bacterial therapies for cancer | $49M | 110 mo ago | 6 | Tetsuya Mishima CEO & President | — | Deadpooled | — | — |
| 2 | SymBio Pharma SymBio Pharmaceuticals engages in in-license, development, and commercialization of drugs for the therapeutic… | $24M | 186 mo ago | 152 | — | Apache HTTP ServerCloudflareGoogle Hosted Libraries+6 | Public | — | — |
| 3 | Noile-Immune Biotech Developer of next-gen CAR-T immunotherapy platform for solid tumors | $22M | 65 mo ago | 28 | — | Apache HTTP ServerAmazon Web ServicesUmami+7 | Public | 134 patents Patents concentrated in chemistry & materials | — |
| 4 | SONIRE Therapeutics Developer of high intensity focused ultrasound treatment systems | $17M | 5 mo ago | 17 | Tohru Satoh Founder & CEO & President | WordPressMySQLPHP+12 | Series B | 59 patents High‑intensity focused ultrasound (HIFU) therapeutic and imaging devices for medical treatment | — |
| 5 | B dot Medical Developer of proton beam therapeutic devices for the treatment of cancer | $13M | 11 mo ago | 58 | Takuji Furukawa President & CEO | — | Series B | 65 patents Advanced charged particle therapy beam steering and integrated patient transport/monitoring systems | — |
| 6 | Craif Developer of a device for cancer detection | $11M | 16 mo ago | 12 | Takao Yasui Co-Founder | microCMSApple iCloud MailGoogle Workspace+15 | Series C | 48 patents Molecular diagnostics and bioseparation microfluidic technologies for nucleic acids and extracellular vesicles | — |
| 7 | Celaid Therapeutics Developer of cell therapies for the treatment of blood cancer | $10M | 11 mo ago | 8 | Masatoshi Sakurai Co-Founder | — | Series B | 7 patents Cell cryopreservation, stem cell culture media, and related pharmaceutical formulations | — |
| 8 | Tella Dendritic cell vaccine for WT1 peptide | $9M | 110 mo ago | 30 | — | WordPressMySQLPHP+15 | Deadpooled | 34 patents Engineered T‑cell/NK‑cell immunotherapies and peptide cancer vaccines targeting WT1 and survivin | — |
| 9 | Red Arrow Therapeutics Provider of nanomedicine technology development services | $5M | 28 mo ago | 9 | — | — | Seed | — | — |
| 10 | KORTUC Developer of radiosensitizer for cancer therapy | $5M | 14 mo ago | 5 | Kazuyuki Matsuda CEO | WordPressMySQLPHP+12 | Series B | 104 patents Stable hydrogen peroxide delivery devices for medical/oncology applications | — |
| 11 | Lily MedTech A diagnostic imaging equipment for breast cancer detection | $3M | 101 mo ago | 17 | Shiho Azuma CEO | WordPress Block EditorWordPressMySQL+20 | Series A | 39 patents Ultrasonic medical imaging diagnostics and automated system malfunction detection | — |
| 12 | Socium Provider of AI-enabled platform for drug discovery and development | $2M | 62 mo ago | 10 | Manabu Takahashi Co-Founder & CEO | — | Series A | 11 patents Patents concentrated in health & consumer products | — |
| 13 | HISHOH Biopharma Developer of immunotherapy for allergies | $2M | 61 mo ago | — | Naoki Sakurai CEO | — | Seed | — | — |
| 14 | HuLa immune Developer of therapeutic agents for autoimmune diseases and cancer treatment | $2M | 78 mo ago | 11 | Yasuhiro Shindo CEO & President | — | Seed | — | — |
| 15 | PhotoQ3 Developer of therapeutic technology for cancer treatment | $2M | 56 mo ago | 4 | Takao Hamakubo CEO | — | Seed | 18 patents Photodynamic therapy agents and tumor‑targeting drugs for cancer cell ablation | — |
| 16 | TKG Therapeutics Developer of therapeutics for cancer patients | $1M | 31 mo ago | — | Masaaki Matsui CEO | — | Seed | 2 patents Synthetic nucleic acid production and pharmaceutical nucleic acid assembly technologies | — |
| 17 | MediGear International Developer of nano-devices therapy for the treatment of cancer | $882K | 93 mo ago | 1 | — | — | Seed | — | — |
| 18 | Liquid Mine Developer of monitoring test system for early detection of leukemia recurrence | $768K | 15 mo ago | 4 | Tomoka Kishimoto CEO | — | Series A | — | — |
| 19 | Daiichi Sankyo Developer of drugs to address diverse medical needs | $236K | 60 mo ago | 32,791 | Sunao Manabe CEO | DNNApple iCloud MailMicrosoft 365+13 | Public | 7,787 patents Oncology antibody‑drug conjugates and multispecific immunotherapies targeting tumor antigens | — |
Top 12 Oncology companies in Tokyo
#1
Series B · Tokyo, Tokyo · founded 2020 · 17 employees$17Mraised▾
Developer of high intensity focused ultrasound treatment systems. The companys system uses cavitation bubbles to enhance treatment efficacy and visualize the treatment process using heating systems. It offers treatment of pancreatic cancer using clinical trial assessing methods. It involves treating disease with high-energy ultrasound waves on a targeted area to destroy the cancer cells.
- Apr 2026Series B$18M
- Nov 2022Series B$17M
- Jun 2021Series A$4.8M
#2
Series B · Edogawa City, Tokyo · founded 2017 · 58 employees$13.1Mraised▾
Developer of proton beam therapeutic devices for the treatment of cancer. The company is involved in the development of an ultra-small proton beam cancer treatment device that uses a beam of protons to deliver radiation directly to the tumor cell. It is a cancer-killing machine that can target a patient's tumor with a sub-millimeter precision while sparing nearby healthy tissues and minimizing side effects.
- Oct 2025Series B$8.8M
- Jun 2022Series A$13.1M
#3
Series B · Bunkyo, Tokyo · founded 2020 · 8 employees$10.2Mraised▾
Developer of cell therapies for the treatment of blood cancer. The company is developing hematopoietic stem cell therapy by using amplification technology for the treatment of blood cancers such as leukemia, malignant lymphoma, multiple myeloma, and intractable blood diseases such as aplastic anemia.
- Oct 2025Series B$7.2M
- May 2024Series A$3M
#4
Series C · Tokyo, Tokyo · founded 2018 · 12 employees$11.3Mraised▾
Developer of a device for cancer detection. The company has developed a novel device that is used to collect and separate the microRNA secreted from cancer cells present in the urine. The device uses a combination of zinc oxide nanostructures and microflow channel technologies for the process and early cancer detection.
- Apr 2025Series C$22M
- Dec 2024Series C$6.4M
- Mar 2024Series B—
- Apr 2022Series B—
#5
Series B · Minato City, Tokyo · founded 2015 · 5 employees$5Mraised▾
Kortuc develops radiosensitizer for cancer therapy. The radiosensitize increases the effectiveness of radiotherapy for cancer. It refers to a cancer treatment method in which a mixture of hydrogen peroxide and hyaluronic acid is injected into tumors and a mixture of therapies.
- Jun 2025Series B$5M
- Jul 2021Seed—
- Dec 2019Seed—
#6
Series A · Shibuya, Tokyo · founded 2019 · 4 employees$767.9Kraised▾
Developer of monitoring test system for early detection of leukemia recurrence. The company is engaged in the development of in-vitro diagnostics for the treatment of cancer patients through genetic analysis.
- May 2025Series A—
- Feb 2023Seed$767.9K
- Feb 2021Seed—
#7
Seed · Bunkyo, Tokyo · founded 2021 · 9 employees$5.3Mraised▾
Provider of nanomedicine technology development services
- Apr 2024Seed$4.5M
- Feb 2022Grant (prize money)—
- Dec 2021Seed$800K
#8
Deadpooled · Chiyoda City, Tokyo · founded 2004 · 6 employees$49.3Mraised▾
Anaeropharma Science is focussed on developing therapies to target hypoxic environment in solid cancers. Its proprietary platform technology, i-DPS (in situ Delivery and Production System) modifies a non-pathogenic anaerobic bacteria, B. longum, which localizes and proliferates in the anaerobic environment and has the potential to produce anticancer proteins, enzymes or other pharmacologically active molecules at the tumor site. Its lead candidate APS001F is a recombinant anaerobic bacteria B. longum and is currently undergoing phase 1/2 trials in US for metastatic solid tumors. Additionally, it has 3 candidates in preclinical development for cancer and Ischemia.
- Jul 2017Series A$13.2M
- Feb 2012Series A$27.7M
- Nov 2010Series A$8.4M
#9
Public · Tokyo, Tokyo · founded 2015 · 28 employees$21.9Mraised▾
Developer of next-gen CART-T immunotherapy platform for solid tumors. The company is developing CAR-T therapies for hematological cancers. To improve the efficacy of CAR-T cells in solid tumors, the company has developed an enhanced CAR-T platforms.
- Mar 2021Series C$21.9M
- Mar 2020Series B—
#10
Public · Minato City, Tokyo · founded 2005 · 152 employees$24Mraised▾
Symbio Pharmaceuticals develops and commercializes prescription drugs in oncology for Japan and other Asia Pacific markets. Pipeline products in various stages of clinical trials include SyB P-1501 (phase 1), SyBL-0501 (market approval for non-hodgkin's lymphoma and relapsed mantle cell lymphoma), SyB L-1101 (phase 3 for relapsed myelodysplastic syndromes) and SyB C-1101 (phase 1 for high risk myelodysplastic syndromes). It has entered into licensing agreement with medicines co. and Onconova therapeutics to develop and commercialize ionsys fentanyl iontophoretic transdermal system and drug candidate rigosertib in japan.
- Feb 2011Series B$24M
#11
Seed · Bunkyo, Tokyo · founded 2022$1Mraised▾
Developer of therapeutics for cancer patients. It offers Oncolytic Hairpin DNA Pair technology for development of immune-activating therapy that targets cancer cells with high miRNA expression. It induces innate immune activation, that targets the cGAS-STING pathway to kill cancer cells.
- Jan 2024Seed$1M
#12
Deadpooled · Tokyo, Tokyo · founded 2004 · 30 employees$8.9Mraised▾
Tella is a Japanese, early-stage biopharma developing dendritic-cell vaccines. Tella has the exclusive license for the cancer marker WT1 peptide and its use in Dendritic Vaccines. The company has developed the treatment for 11410 patients as on Jun.2017. The therapy is not covered by public health insurance in Japan.
- Jul 2017Post IPO$8.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology in Tokyo is moving
A read on the academic research around Oncology in Tokyo — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 156 papers.
- The University of Tokyo76
- Tokyo Medical University25
- Tokyo Medical and Dental University21
- Tokyo University of Science11
- University of Tokyo Hospital11
- Tumor microenvironment2→25
- Cancer research1→16
- T cell1→3
- Cancer research1→31
- Cell biology1→4
- Immunotherapy7
- Immune system6
- Cancer research4
- Tumor microenvironment3
- Cancer3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.